Tcr2 Therapeutics (NASDAQ:TCRR) Upgraded to Hold at BidaskClub

Tcr2 Therapeutics (NASDAQ:TCRR) was upgraded by BidaskClub from a “sell” rating to a “hold” rating in a research report issued on Tuesday, BidAskClub reports.

A number of other equities research analysts also recently weighed in on TCRR. Piper Sandler assumed coverage on Tcr2 Therapeutics in a research report on Wednesday, August 12th. They set an “overweight” rating and a $35.00 price objective on the stock. ValuEngine raised Tcr2 Therapeutics from a “hold” rating to a “buy” rating in a research report on Monday, August 3rd. HC Wainwright dropped their price objective on Tcr2 Therapeutics from $33.00 to $32.00 and set a “buy” rating on the stock in a research report on Thursday, August 13th. Roth Capital raised Tcr2 Therapeutics from a “neutral” rating to a “buy” rating and raised their price objective for the company from $16.00 to $35.00 in a research report on Monday, July 27th. Finally, Mizuho assumed coverage on Tcr2 Therapeutics in a research report on Thursday, August 20th. They set a “buy” rating on the stock. Two research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. Tcr2 Therapeutics has an average rating of “Buy” and a consensus price target of $28.83.

TCRR opened at $19.29 on Tuesday. Tcr2 Therapeutics has a 12-month low of $5.84 and a 12-month high of $20.94. The business’s fifty day simple moving average is $18.17 and its 200-day simple moving average is $13.15. The company has a market capitalization of $643.21 million, a price-to-earnings ratio of -7.91 and a beta of 1.97.

Tcr2 Therapeutics (NASDAQ:TCRR) last posted its quarterly earnings results on Wednesday, August 12th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.02). On average, equities analysts forecast that Tcr2 Therapeutics will post -2.35 EPS for the current fiscal year.

A number of institutional investors have recently added to or reduced their stakes in TCRR. Granite Point Capital Management L.P. purchased a new stake in Tcr2 Therapeutics in the second quarter valued at about $1,536,000. ArrowMark Colorado Holdings LLC raised its stake in Tcr2 Therapeutics by 7.3% in the first quarter. ArrowMark Colorado Holdings LLC now owns 1,362,653 shares of the company’s stock valued at $10,547,000 after buying an additional 92,887 shares during the last quarter. DAFNA Capital Management LLC purchased a new stake in Tcr2 Therapeutics in the first quarter valued at about $610,000. Nuveen Asset Management LLC raised its stake in shares of Tcr2 Therapeutics by 116.2% in the second quarter. Nuveen Asset Management LLC now owns 80,384 shares of the company’s stock worth $1,235,000 after purchasing an additional 43,210 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. purchased a new position in shares of Tcr2 Therapeutics in the second quarter worth about $643,000. Institutional investors own 45.52% of the company’s stock.

About Tcr2 Therapeutics

TCR2 Therapeutics Inc, a clinical-stage immunotherapy company, develops novel T cell receptor therapies for patients suffering from cancer. Its product candidates in pipeline comprise TC-210 mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors; TC-220 that targets MUC16 positive solid tumors; and TC-310 and TC-410 dual TRuC-T cell programs targeting CD19/22 and MSLN/MUC16, as well as TC-110 mono TRuC-T cells targeting CD19-positive B-Cell hematological malignancies.

Further Reading: What is basic economics?

Analyst Recommendations for Tcr2 Therapeutics (NASDAQ:TCRR)

Receive News & Ratings for Tcr2 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tcr2 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.